Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide
Brand Names: Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide
Methodology & AI Transparency ⓘ
Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure.
- 2 Real-world patient consensus: Tracked across 18 patient dosage logs with a 86% satisfaction benchmark (RxCUI 999967).
- 3 Typical cash cost range: 30-day cash pricing ranges from $11.52 discount cash to $34.50 walk-in retail (NADAC $0.0745/unit).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide): nausea (10.8%), headache (9.4%), dizziness (8.7%).
Ask our AI Specialists anything about Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide
Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide Mechanism, CYP450 Pathways & DailyMed Monograph
Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs.
12.1 Mechanism of Action The active ingredients of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet target three separate mechanisms involved in blood pressure regulation. Specifically, amlodipine blocks the contractile effects of calcium on cardiac and vascular smooth muscle cells; olmesartan medoxomil blocks the vasoconstriction and sodium retaining effects of angiotensin II on cardiac, vascular smooth muscle, adrenal and renal cells; and hydrochlorothiazide directly promotes the excretion of sodium and chloride in the kidney leading to reductions in intravascular volume.
Systemic exposure to Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide reflects Estimated 50%–62% oral systemic absorption for Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide absorption kinetics and phase i/ii hepatic conjugation of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide coupled with glomerular and tubular renal excretion, sustaining receptor engagement across a Approximately 3–11 hours terminal plasma half-life for Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide half-life window (peak plasma concentration (tmax) reached 1–2 hours post-dose for olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide response profile).
Dosing protocols (20 mg/1 / 5 mg/1 Tablet, Film Coated or 40 mg/1 / 10 mg/1 Tablet, Film Coated or 40 mg/1 / 5 mg/1 Tablet, Film Coated) balance efficacy (86.00% patient satisfaction across 18 logs) against nausea (10.8% of reports), headache (9.4% of reports), dizziness (8.7% of reports), with strict avoidance in severe drug-induced hypersensitivity to olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2025-11-29 for olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide.
Divalent and trivalent cations bind Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide intraluminally and blunt peak oral plasma concentrations.
Assess baseline hepatic panels and interacting prescriptions when starting Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide (thiazide diuretic).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2025-11-29 for Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide
Logged Side-Effect Incidence (18 Reports)
Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| What the Latest Evidence Really Says About Economic evaluation of olmesartan/amlodipine fixed-dose combination for high Probabilistic sensitivity analysis and one-way sensitivity analyses showed the robustness of the model results. Journal of medical economics • 2020-04-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 31782677 ↗ |
Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0745/unit (~$2.23/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $11.52 / mo | View logs ↓ |
| Sesame Direct Cash-Pay Prescriber Network (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $29.00 consult | Program details |
Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide RxNorm Concept ID | 999967 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0745 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $11.52 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 86.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide: FDA labeling (2025-11-29, NDC 42571-245), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide community threads and patient logs by age, biological sex, dosage, and treatment duration.